MT10109L in the Treatment of Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

December 24, 2018

Primary Completion Date

March 13, 2020

Study Completion Date

January 25, 2021

Conditions
Glabellar Lines
Interventions
DRUG

MT10109L

MT10109L will be injected into the GL.

DRUG

Placebo

Placebo will be injected into the GL.

Trial Locations (15)

1090

Universitair Ziekenhuis Brussel, Brussels

3800

Medical Skin Care, Sint-Truiden

4000

CHU Liege, Liège

6280

Centre de la Fontaine, Loverval

10028

Dermatology and Laser Surgery Center of New York, New York

14623

SkinSearch of Rochester, Inc., Rochester

27612

M3 Wake Research, Inc., Raleigh

34209

Weinkle Dermatology, Bradenton

43016

Aventiv Research, Inc., Dublin

70130

Etre, Cosmetic Dermatology and Laser Center, New Orleans

78746

Westlake Dermatology & Cosmetic Surgery, Austin

85255

Investigate MD, Scottsdale

92075

Art of Skin MD, Solana Beach

109369

Medical Centre Capital-Zdorovie, Moscow

420105

Kazan State Medical University, Kazan'

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03795922 - MT10109L in the Treatment of Glabellar Lines | Biotech Hunter | Biotech Hunter